ArticleClinical research in cardiology : official journal of the German Cardiac Society2006
ACE inhibition in secondary prevention: are the results controversial?
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Association Between Irbesartan and Erectile Dysfunction: A Comprehensive Analysis Incorporating Real-World Pharmacovigilance and Mendelian Randomization.Hospital pharmacy · 2026Article
- Metabolic Syndrome-Associated Erectile Dysfunction: Multiple Vascular Endothelial Dysfunction Mechanisms and Potential Therapeutic Targets.International journal of biological sciences · 2025Review
- Oxidative Stress and Erectile Dysfunction: Pathophysiology, Impacts, and Potential Treatments.Current issues in molecular biology · 2024Review
- Hypertensive goals in patients with coronary artery disease.Current cardiology reports · 2012Review
- Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis.British journal of pharmacology · 2011Article
- Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials.Vascular health and risk management · 2011Review
- Recent achievements in the management of Raynaud's phenomenon.Vascular health and risk management · 2010Review
- ACE inhibitors - angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease.Open access emergency medicine : OAEM · 2010Review
- The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies.Mediators of inflammation · 2009Review
- Prehospital cooling with hypothermia caps (PreCoCa): a feasibility study.Clinical research in cardiology : official journal of the German Cardiac Society · 2008Article
- RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.Clinical research in cardiology : official journal of the German Cardiac Society · 2008Review
- Hotline update of clinical trials and registries presented at the ACC and SCAI-ACCi2 meeting 2008 in Chicago.Clinical research in cardiology : official journal of the German Cardiac Society · 2008Article
- Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy.Clinical research in cardiology : official journal of the German Cardiac Society · 2008Article
- Lichenoid reactions to gold from dental restorations and exposure to gold through intracoronary implant of a gold-plated stent.Clinical research in cardiology : official journal of the German Cardiac Society · 2006Article
- Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome.International journal of impotence researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Results from the HOPE and EUROPA trials showed that ACE inhibitors lower cardiovascular mortality of patients with atherosclerosis and preserved left ventricular function. However, despite apparently adequate study design, the recently conducted PEACE trial detected no benefit of an additional ACE inhibitor treatment in patients with coronary artery disease and no heart failure with respect to cardiovascular risk reduction. One of the main reasons for this discrepancy might be the lower cardiovascular baseline risk of the PEACE study population, which was more intensively treated with lipid lowering drugs and myocardial revascularization prior to enrollment than patients in HOPE or EUROPA. Another reason for the negative results of PEACE might be substance-specific differences between individual ACE inhibitors (trandolapril in PEACE, ramipril in HOPE, and perindopril in EUROPA) in their clinical efficacy to reduce cardiovascular end-points. The PEACE trial did not achieve the originally projected sample size and the addition of a soft end-point of revascularization has not been helpful. While the results from the PEACE trial suggest that low-risk patients with coronary artery disease and with preserved left ventricular function who receive intensive standard therapy including lipid lowering and coronary revascularization may not benefit from additional ACE inhibition therapy, this conclusion should be made with caution. A number of reasons, other than drug treatment efficacy, may explain the neutral results in the PEACE trial. Further studies are needed to try to resolve this issue. In the meantime, the overwhelming data still support the use of ACE inhibitors in patients with coronary artery disease with preserved left ventricular function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.